- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Primary Biliary Cholangitis
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Elafibranor – March 2025
Elafibranor; Tablet 80 mg; Iqirvo®
Last updated
12 March 2025